| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33084 | |||
| IHC-Prediluted | NBP2-44524 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-616SS | |||
| Azide and BSA Free | NBP2-80820 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-704SS | |||
| Azide and BSA Free | NBP2-80725 | |||
![Immunohistochemistry-Paraffin: p21/CIP1/CDKN1A Antibody (WA-1) [NBP2-29463] - Formalin-fixed, paraffin-embedded human bladder carcinoma stained with p21 Monoclonal Antibody (WA-1).](http://images.novusbio.com/fullsize/p21-CIP1-CDKN1A-Antibody-WA-1-Immunohistochemistry-Paraffin-NBP2-29463-img0001.jpg "Immunohistochemistry-Paraffin: p21/CIP1/CDKN1A Antibody (WA-1) [NBP2-29463] - Formalin-fixed, paraffin-embedded human bladder carcinoma stained with p21 Monoclonal Antibody (WA-1).")
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - Mouse intestine. RBPMS stained by RBPMS antibody diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/RBPMS-Antibody-Immunohistochemistry-Paraffin-NBP2-20112-img0012.jpg "Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - Mouse intestine. RBPMS stained by RBPMS antibody diluted at 1:2000.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.")
![Western Blot: RBPMS Antibody [NBP2-20112] - Various whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with RBPMS antibody (NBP2-20112) diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-91020242091455.jpg)
![Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunohistochemical analysis.Sample: Paraffin-embedded mouse lymph node.RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-91020242021960.jpg)
![Immunohistochemistry-Paraffin: RBPMS Antibody [NBP2-20112] - RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunohistochemical analysis.Sample: Paraffin-embedded rat colon.RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-910202420131234.jpg)
![Immunocytochemistry/ Immunofluorescence: RBPMS Antibody [NBP2-20112] - RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunofluorescent analysis.Sample: A549 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody [GT114] diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-91020242011420.jpg)
![RBPMS antibody detects RBPMS protein at cytoplasm and nucleus by immunofluorescent analysis.Sample: A431 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: RBPMS stained by RBPMS antibody (NBP2-20112) diluted at 1:500.Red: alpha Tubulin, a cytoskeleton marker, stained by alpha Tubulin antibody [GT114] diluted at 1:1000.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-immunocytochemistry-immunofluorescence-26112025182700.jpg)
![RBPMS antibody detects RBPMS protein by immunohistochemical analysis. Samples: Paraffin-embedded mouse retina.Green: RBPMS protein stained by RBPMS antibody (NBP2-20112) diluted at 1:250.Red: beta Tubulin 3/ Tuj1, a marker, stained by beta Tubulin 3/ Tuj1 antibody [GT1338] diluted at 1:500.Blue: Fluoroshield with DAPI . br>Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-20112_rabbit-polyclonal-rbpms-antibody-immunohistochemistry-paraffin-261120251819361.jpg)
![Western Blot: DNA Ligase I Antibody (10H5) [NB100-119] - Various whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with DNA ligase I antibody [10H5] diluted at 1:2000. The HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/DNA-Ligase-I-Antibody-10H5-Western-Blot-NB100-119-img0003.jpg "Western Blot: DNA Ligase I Antibody (10H5) [NB100-119] - Various whole cell extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with DNA ligase I antibody [10H5] diluted at 1:2000. The HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody.")
![Immunocytochemistry/Immunofluorescence: DNA Ligase I Antibody (10H5) [NB100-119] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: DNA ligase I stained by DNA ligase I antibody [10H5] diluted at 1:500. Red: phalloidin, a cytoskeleton marker, diluted at 1:200. Scale bar= 10 um.](http://images.novusbio.com/fullsize/DNA-Ligase-I-Antibody-10H5-Immunocytochemistry-Immunofluorescence-NB100-119-img0004.jpg)
![Immunohistochemistry-Paraffin: DNA Ligase I Antibody (10H5) [NB100-119] - Human breast carcinoma. DNA ligase I stained by DNA ligase I antibody [10H5] diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/DNA-Ligase-I-Antibody-10H5-Immunohistochemistry-Paraffin-NB100-119-img0001.jpg)
![Simple Western: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Simple Western lane view shows a specific band for Histone H2AX [p Ser139] in 0.2 mg/ml of Jurkat lysate(s). This experiment was performed under reducing conditions using the 12 - 230 kDa separation system.](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Simple-Western-NB100-74435-img0012.jpg "Simple Western: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Simple Western lane view shows a specific band for Histone H2AX [p Ser139] in 0.2 mg/ml of Jurkat lysate(s). This experiment was performed under reducing conditions using the 12 - 230 kDa separation system.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Staining of Phospho-H2AX in A549 cells. Cells were treated with 50 uM EPE for 1 hour (left panel) or with vehicle (right control: 0.1% DMSO in media).](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Immunocytochemistry-Immunofluorescence-NB100-74435-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Staining using NB100-74435, treatment with paraquat and iron induces MnSOD and Phosphorylation of H2AX in RAW 264.7 macrophages. Cells were treated for 20 hours with paraquat (500 uM) and iron (200 ug/ml) and stained with anti-Phospho-H2AX antibody.](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Immunocytochemistry-Immunofluorescence-NB100-74435-img0008.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Western blot analysis of Jurkat cells (Lane 1) and Jurkat cells treated with staurosporine (Lane 2) blotted with Histone H2AX [p Ser139] antibody (3F2). Bands indicate an observed molecular weight of ~16 kDa.](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Western-Blot-NB100-74435-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - STED image of MDA-MB-231 cells after 2 Gy irradiation. Blue channel: DAPI, window level [0 255]. Green channel: secondary antibody Alexa Fluor 488, window level [140 255]. Scale bar: 20 um. Image from verified customer review.](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Immunocytochemistry-Immunofluorescence-NB100-74435-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Immunofluorescence analysis using Histone H2AX [p Ser139] antibody (3F2).](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Immunocytochemistry-Immunofluorescence-NB100-74435-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - IF image of phosphorylated H2AX in gamma irradiated Hela cells.](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Immunocytochemistry-Immunofluorescence-NB100-74435-img0015.jpg)
![Simple Western: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Electropherogram image(s) of corresponding Simple Western lane view. Histone H2AX [p Ser139] antibody (3F2) was used at 10 ug/ml dilution on Jurkat lysate(s).](http://images.novusbio.com/fullsize/gamma-H2AX-p-Ser139-Antibody-3F2-Simple-Western-NB100-74435-img0013.jpg)
![Immunocytochemistry/ Immunofluorescence: Histone H2AX [p Ser139] Antibody (3F2) [NB100-74435] - Evidence of DNA damage & oxidative stress in islets from HFD treated mice. (a) Representative immunofluorescent staining of gamma H2AX, insulin, & DAPI for islets from each treatment group. (b) Representative immunofluorescent staining of 4-hydroxynonenal (4-HNE), insulin, & DAPI for islets from each treatment group. (c) Representative immunofluorescent staining of nitrotyrosine, insulin, & DAPI for islets from each treatment group. (d–g) qRT-PCR analysis of total islet RNA for antioxidant genes, including Gpx1, SOD1, Nrf2, & Ppargc1 alpha . (n = 3) *p < 0.05, **p < 0.01. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-03869-5), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74435_mouse-monoclonal-histone-h2ax-p-ser139-antibody-3f2-31020241534396.jpg)
![Western Blot: Menin Antibody [NB100-215] - Whole cell lysate (50 ug) from TCMK-1 and NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Menin antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/Menin-Antibody-Western-Blot-NB100-215-img0009.jpg "Western Blot: Menin Antibody [NB100-215] - Whole cell lysate (50 ug) from TCMK-1 and NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Menin antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: Menin Antibody [NB100-215] - Section of human lung carcinoma. Antibody: Affinity purified rabbit anti-Menin used at a dilution of 1:1,000 (1ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/Menin-Antibody-Immunohistochemistry-Paraffin-NB100-215-img0010.jpg)
![Western Blot: Menin Antibody [NB100-215] - Whole cell lysate (50 ug) from HeLa, HEK293T, and Jurkat cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Menin antibody used for WB at 0.04 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/Menin-Antibody-Western-Blot-NB100-215-img0008.jpg)
![Immunoprecipitation: Menin Antibody [NB100-215] - Detection of human Menin by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-Menin antibody NB100-215 (lot 2) used for IP at 6 ug per reaction. Menin was also immunoprecipitated by a previous lot of this antibody (lot 1). For blotting immunoprecipitated Menin, NB100-215 was used at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 seconds.](http://images.novusbio.com/fullsize/Menin-Antibody-Immunoprecipitation-NB100-215-img0007.jpg)
![Immunocytochemistry/ Immunofluorescence: 53BP1 Antibody Pack [NB100-926] - 53BP1 was detected in immersion fixed HeLa cells (left) but was not detected in 53BP1 knockout Hela cells (right) using Rabbit Anti-human 53BP1 polyclonal antibody (Catalog #NB100-304) at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to nuclei.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Knockout-Validated-NB100-926-img0020.jpg "<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: 53BP1 Antibody Pack [NB100-926] - 53BP1 was detected in immersion fixed HeLa cells (left) but was not detected in 53BP1 knockout Hela cells (right) using Rabbit Anti-human 53BP1 polyclonal antibody (Catalog #NB100-304) at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to nuclei.")
![<b>Genetic Strategies Validation. </b>Western Blot: 53BP1 Antibody Pack [NB100-926] - Western blot analysis of human 53BP1, blotted with 53BP1 antibody (Catalog #NB100-305). Sample: Whole cell lysate (20 ug/lane) from U2Os cells resolved on a 3 to 8% trisacetate gel. A band appears at approximately the theoretical molecular weight of 214 kDa.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Western-Blot-NB100-926-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: 53BP1 Antibody Pack [NB100-926] - Exosomes modulate the repair of DNA DSBs in irradiated recipient cells. Representative images of 53BP1 foci in BHY cells 6 hours after 2 Gy and transfer of BHY exosomes isolated 24 hours after irradiation with 0, 3, 6 or 9 Gy (53BP1 foci green, nuclei blue) using NB100-305. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0152213), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Immunocytochemistry-Immunofluorescence-NB100-926-img0017.jpg)
![Immunohistochemistry: 53BP1 Antibody Pack [NB100-926] - Immunohistochemical analysis of human breast tumors stained with 53BP1 antibody (Catalog #NB100-304). Image from verified customer review.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-NB100-926-img0021.jpg)
![Flow Cytometry: 53BP1 Antibody Pack [NB100-926] - An intracellular stain was performed on HeLa cells with 53BP1 Antibody (Catalog #NB100-305AF488) (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Flow-Cytometry-NB100-926-img0023.jpg)
![Western Blot: 53BP1 Antibody Pack [NB100-926] - Detection of Human [deleted mouse] 53BP1 by Western Blot on Whole cell lysate from U2OS or 293T cells resolved on a 3 to 8% tris-acetate gel using 53BP1 Antibody (Catalog #NB100-304).](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Western-Blot-NB100-926-img0009.jpg)
![Immunohistochemistry: 53BP1 Antibody Pack [NB100-926] - Immunohistochemical staining of placental villi with 53BP1 Antibody (Catalog #NB100-305) at 40X magnification.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Immunohistochemistry-NB100-926-img0012.jpg)
![Flow Cytometry: 53BP1 Antibody Pack [NB100-926] - Detection of 53BP1. 1 million Jurkat cells were fixed, permeabilized, and stained with 1.5 mcg/ml 53BP1 Antibody (Catalog #NB100-304) in a 150 mcl reaction. Isotype control (black), anti-53bp1 (red).](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Flow-Cytometry-NB100-926-img0010.jpg)
![Flow Cytometry: 53BP1 Antibody Pack [NB100-926] - An intracellular stain was performed on RH-30 cells with 53BP1 Antibody (Catalog #NB100-304AF647) (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/53BP1-Antibody-Pack-Flow-Cytometry-NB100-926-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW105)) at 5ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Immunocytochemistry-Immunofluorescence-NB100-616-img0005.jpg "Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B Antibody (RW105)) at 5ug/ml for 60 minutes at room temperature and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective.")
![Western Blot: KAT3B/p300 Antibody (RW105) [NB100-616] - p300 detected in a HeLa nuclear extract using NB 100-616 (1:250). ECL: 20 minute exposure.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Western-Blot-NB100-616-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: KAT3B/p300 Antibody (RW105) [NB100-616] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-KAT3B/p300 Antibody (RW105) NB100-616 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Immunocytochemistry-Immunofluorescence-NB100-616-img0008.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on RAW 246.7 cells with KAT3B/p300 antibody (RW105) NB100-616PE (blue) and a matched isotype control NBP2-27287PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin. Image using the PE format of this antibody.](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Cytometry-NB100-616-img0006.jpg)
![Flow (Intracellular): KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on THP-1 cells with KAT3B/p300 (RW105) antibody NB100-616 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and permeabilized with 0.1% Saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Intracellular-NB100-616-img0003.jpg)
![Flow Cytometry: KAT3B/p300 Antibody (RW105) [NB100-616] - An intracellular stain was performed on Raw264.7 cells with KAT3B/p300 Antibody (RW105) NB100-616 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/KAT3B-p300-Antibody-RW105-Flow-Cytometry-NB100-616-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: KAT3B/p300 Antibody (RW105) [NB100-616] - 293T cells were treated with different siRNAs against p300 alone for 2 days and core histones were prepared and subjected to WB analysis as indicated. The knockdown efficiency of p300 was confirmed by WB analysis of cell lysates. Western Blot protocol is 6% gel for running, 40V overnight transfer membrane. primary Ab 1:500, secondary Ab 1:5000. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-616_mouse-monoclonal-kat3b-p300-antibody-rw105-knockdown-validated-147202311647.jpg)
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Cyto-histologic comparison of anti-ERCC1 immunoreactivity using the protocol 8F1 CC1-mono (top) or 8F1 H2-60 (bottom). Left: Pleural effusion sediment of lung adenocarcinoma. Right: thoracic lymph node. Arrow: Lymphocyte. Arrowhead: Streak of endothelial cells. Asterisk: Tumor cell cluster. 400 A- original magnification. Image collected and cropped by Citeab from the following publication (Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma (2011) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0004.jpg "Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Cyto-histologic comparison of anti-ERCC1 immunoreactivity using the protocol 8F1 CC1-mono (top) or 8F1 H2-60 (bottom). Left: Pleural effusion sediment of lung adenocarcinoma. Right: thoracic lymph node. Arrow: Lymphocyte. Arrowhead: Streak of endothelial cells. Asterisk: Tumor cell cluster. 400 A- original magnification. Image collected and cropped by Citeab from the following publication (Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma (2011) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Analysis of ERCC1 in human non-small cell lung cancer. Image courtesy of product review submitted by Alex Soltermann.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0002.jpg)
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Formalin fixed paraffin embedded human tonsil stained with ERCC1 antibody.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0003.jpg)
![Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Anti-ERCC1 immunohistochemistry on whole sections of a lung squamous cell carcinoma, using Mab 8F1 and D-10 with CC1-mono and H2-60 protocols. Note increased cytosolic background with H2-60. Arrow: Necrotic centre. Arrowhead: Stromal axis. 100 A- original magnification. Image collected and cropped by Citeab from the following publication (Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. J Clin Bioinforma (2011) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ERCC1-Antibody-8F1-Immunohistochemistry-Paraffin-NB500-704-img0005.jpg)
![Immunohistochemistry: ERCC1 Antibody (8F1) - BSA Free [NB500-704] - Anti-ERCC1 immunocytochemistry on cell block core of malignant pleural mesothelioma, using Mab 8F1 & D-10 with CC1-mono & H2-60 protocols. Arrow: Surrounding non-tumoral cells, including lymphocytes, macrophages & neutrophil granulocytes. Arrowhead: Unspecific plasma membrane staining with D-10. 200 × original magnification. Inset lower left: Staining of intracellular mucin vacuoles of a mucinous adenocarcinoma of unknown origin. 400 × original magnification. Image collected & cropped by CiteAb from the following publication (//jclinbioinformatics.biomedcentral.com/articles/10.1186/2043-9113-1-25), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-704_mouse-monoclonal-ercc1-antibody-8f1-310202415171338.jpg)
![Western Blot: TERF2IP Antibody [NB100-292] - Detection of Human RAP1 by Western Blot. Samples: Whole cell lysate (15 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-RAP1 antibody NB100-292 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/TERF2IP-Antibody-Western-Blot-NB100-292-img0019.jpg "<b>Biological Strategies Validation. </b>Western Blot: TERF2IP Antibody [NB100-292] - Detection of Human RAP1 by Western Blot. Samples: Whole cell lysate (15 ug) from HeLa and 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-RAP1 antibody NB100-292 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TERF2IP Antibody [NB100-292] - Sections of human lung carcinoma.~~ Antibody: Affinity purified rabbit anti-RAP1 used at a dilution of 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/TERF2IP-Antibody-Immunohistochemistry-Paraffin-NB100-292-img0014.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: TERF2IP Antibody [NB100-292] - Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinitypurified rabbit anti-RAP1 antibody used for IP at 6 ug per reaction. RAP1 was also immunoprecipitated by a previous lot of this antibody and rabbit anti-RAP1 antibody. For blotting immunoprecipitated RAP1, was used at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/TERF2IP-Antibody-Immunoprecipitation-NB100-292-img0018.jpg)
![Western Blot: FEN-1 Antibody (4E7) [NB100-150] - Whole cell extract (30 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with FEN1 antibody diluted at 1:500.](http://images.novusbio.com/fullsize/FEN-1-Antibody-4E7-Western-Blot-NB100-150-img0006.jpg "Western Blot: FEN-1 Antibody (4E7) [NB100-150] - Whole cell extract (30 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with FEN1 antibody diluted at 1:500.")
![Immunocytochemistry/Immunofluorescence: FEN-1 Antibody (4E7) [NB100-150] - Analysis of paraformaldehyde-fixed MCF7, using antibody at 1:200 dilution.](http://images.novusbio.com/fullsize/FEN-1-Antibody-4E7-Immunocytochemistry-Immunofluorescence-NB100-150-img0004.jpg)
![Western Blot: eIF4G1 Antibody [NB100-268] - Whole cell lysate (50 ug) from HeLa and HEK293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-eiF4G1/eiF4GI antibody used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/eIF4G1-Antibody-Western-Blot-NB100-268-img0001.jpg "Western Blot: eIF4G1 Antibody [NB100-268] - Whole cell lysate (50 ug) from HeLa and HEK293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-eiF4G1/eiF4GI antibody used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![Immunoprecipitation: eIF4G1 Antibody [NB100-268] - Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-eiF4G1/eiF4GI antibody used for IP at 6 ug per reaction. eiF4G1/eiF4GI was also immunoprecipitated by rabbit antieiF4G1/eiF4GI antibody. For blotting immunoprecipitated eiF4G1/eiF4GI, rabbit antieiF4G1/eiF4GI antibody was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.](http://images.novusbio.com/fullsize/eIF4G1-Antibody-Immunoprecipitation-NB100-268-img0003.jpg)